Krystal Biotech Reports $127.3 Million Q3 Revenue and $63.1 Million Net Income

What happened

Krystal Biotech reported third-quarter 2026 net product revenue of $127.3 million, up 30% from a year earlier, and net income of $63.1 million. The company ended September 30 with $1.2 billion in cash, cash equivalents and investments, and its board authorized a share repurchase program of up to $400 million.

Confirmed

Global impact / market context

Revenue growth and operating income rising year over year indicate stronger product sales and operating performance, while net income fell from the prior-year quarter. The authorized buyback could use company cash to reduce shares outstanding, but the article does not say how much will be repurchased or when.

Analyst inference

VYJUVEK demand is expanding in the United States, with more than 760 reimbursement approvals, while the company is pursuing launches and regulatory approvals abroad. Those steps could broaden sales, but launch timing, reimbursement, pricing discussions, and regulatory decisions affect how quickly international revenue develops.

Analyst inference

What to watch

1. Track whether revenue growth continues and whether net income rebounds, since third-quarter net income was below the prior-year result despite higher revenue and operating income. Analyst inference
2. Watch for details on the share repurchase, including timing and the amount actually bought; the board authorized purchases of up to $400 million, not a required spend. Confirmed
3. Follow the expected Italy launch in early 2027 and the planned Swiss application before year-end, as these milestones could affect when overseas sales become possible. Proposed

Evidence

• Original source link unavailable